ChengDa Pharmaceuticals Co. Ltd.
ChengDa Pharmaceuticals Co., Ltd. engages in the research and development, production, and sale of pharmaceutical intermediates, chemical ingredients, and food and feed additives in China and internationally. It offers process research and development, process optimization, quality and stability research, customized production and other services for pharmaceutical intermediates and APIs; and food… Read more
Market Cap & Net Worth: ChengDa Pharmaceuticals Co. Ltd. (301201)
ChengDa Pharmaceuticals Co. Ltd. (SHE:301201) has a market capitalization of $899.95 Million (CN¥6.60 Billion) as of March 19, 2026. Listed on the SHE stock exchange, this China-based company holds position #11219 globally and #2614 in its home market, demonstrating a -5.66% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ChengDa Pharmaceuticals Co. Ltd.'s stock price CN¥42.68 by its total outstanding shares 154713824 (154.71 Million).
ChengDa Pharmaceuticals Co. Ltd. Market Cap History: 2022 to 2026
ChengDa Pharmaceuticals Co. Ltd.'s market capitalization history from 2022 to 2026. Data shows change from $654.44 Million to $899.95 Million (-13.51% CAGR).
ChengDa Pharmaceuticals Co. Ltd. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ChengDa Pharmaceuticals Co. Ltd.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.28x
ChengDa Pharmaceuticals Co. Ltd.'s market cap is 1.28 times its annual revenue
1.00x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $654.44 Million | $411.46 Million | $106.48 Million | 1.59x | 6.15x |
| 2023 | $530.27 Million | $414.30 Million | $90.98 Million | 1.28x | 5.83x |
| 2024 | $425.52 Million | $333.13 Million | -$28.10 Million | 1.28x | N/A |
Competitor Companies of 301201 by Market Capitalization
Companies near ChengDa Pharmaceuticals Co. Ltd. in the global market cap rankings as of March 19, 2026.
Key companies related to ChengDa Pharmaceuticals Co. Ltd. by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #422 globally with a market cap of $51.61 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #432 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #452 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #719 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #422 | Zoetis Inc | NYSE:ZTS | $51.61 Billion | $117.35 |
| #432 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.31 |
| #452 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #719 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
ChengDa Pharmaceuticals Co. Ltd. Historical Marketcap From 2022 to 2026
Between 2022 and today, ChengDa Pharmaceuticals Co. Ltd.'s market cap moved from $654.44 Million to $ 899.95 Million, with a yearly change of -13.51%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥899.95 Million | +4.86% |
| 2025 | CN¥858.20 Million | +101.68% |
| 2024 | CN¥425.52 Million | -19.75% |
| 2023 | CN¥530.27 Million | -18.97% |
| 2022 | CN¥654.44 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of ChengDa Pharmaceuticals Co. Ltd. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $899.95 Million USD |
| MoneyControl | $899.95 Million USD |
| MarketWatch | $899.95 Million USD |
| marketcap.company | $899.95 Million USD |
| Reuters | $899.95 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.